Home » Stocks » RYTM

Rhythm Pharmaceuticals, Inc. (RYTM)

Stock Price: $33.99 USD -0.27 (-0.79%)
Updated Jan 19, 2021 3:36 PM EST - Market open
Market Cap 1.51B
Revenue (ttm) n/a
Net Income (ttm) -132.06M
Shares Out 44.14M
EPS (ttm) -3.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $33.99
Previous Close $34.26
Change ($) -0.27
Change (%) -0.79%
Day's Open 34.30
Day's Range 33.61 - 34.86
Day's Volume 203,094
52-Week Range 13.16 - 34.86

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 weeks ago

BOSTON, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare ge...

GlobeNewsWire - 4 weeks ago

-- Study met primary endpoint and all key secondary endpoints with statistically significant and clinically meaningful reductions in weight and hunger -- -- All primary endpoint responders wer...

GlobeNewsWire - 1 month ago

BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare ge...

Zacks Investment Research - 1 month ago

Rhythm's (RYTM) stock gains as FDA approves its lead product candidate for chronic weight management.

GlobeNewsWire - 1 month ago

-- Indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to POMC, PCSK1 or LEPR deficiency confirmed by genetic testing -- -- Approv...

GlobeNewsWire - 2 months ago

-- Interim d ata from Phase 2 study showed that once-weekly formulation of setmelanotide achieve d safety and efficacy results comparable to daily-dosing formulation -- -- Additional data from...

GlobeNewsWire - 2 months ago

-- NDA for setmelanotide for POMC and LEPR deficiency obesities under review, with PDUFA goal date of November 27, 2020 --  -- Appointed Jennifer Chien and Yann Mazabraud to co-lead global int...

GlobeNewsWire - 2 months ago

Largest studies in POMC and LEPR deficiency obesities demonstrate that treatment with setmelanotide reduced body weight and hunger Largest studies in POMC and LEPR deficiency obesities demonst...

GlobeNewsWire - 2 months ago

BOSTON, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment...

Zacks Investment Research - 3 months ago

Rhythm Pharmaceuticals (RYTM) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

GlobeNewsWire - 4 months ago

– Company announces organizational changes designed to accelerate global strategy –

GlobeNewsWire - 4 months ago

BOSTON, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treat...

Zacks Investment Research - 4 months ago

Rhythm (RYTM) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

GlobeNewsWire - 5 months ago

BOSTON, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatm...

GlobeNewsWire - 5 months ago

-- Appointed David Meeker, M.D., as President and Chief Executive Officer –

GlobeNewsWire - 5 months ago

BOSTON, July 27, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatme...

GlobeNewsWire - 5 months ago

BOSTON, July 20, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatme...

GlobeNewsWire - 6 months ago

-- Study demonstrated that treatment with setmelanotide reduced body weight and hunger in individuals living with Bardet-Biedl syndrome -- BOSTON, July 16, 2020 (GLOBE NEWSWIRE) -- Rhythm ...

GlobeNewsWire - 6 months ago

BOSTON, July 01, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatme...

Seeking Alpha - 6 months ago

Rhythm's Setmelanotide Data And Other News: The Good, Bad And Ugly Of Biopharma

GlobeNewsWire - 6 months ago

-- Once-weekly formulation of setmelanotide achieved weight loss efficacy comparable to daily-dosing formulation –

GlobeNewsWire - 8 months ago

– FDA grants Priority Review of application and sets PDUFA goal date of November 27, 2020 –

GlobeNewsWire - 9 months ago

 Hunter Smith, Chief Financial Officer, appointed Interim Chief Executive Officer following completion of NDA submission to FDA 

GlobeNewsWire - 9 months ago

BOSTON, March 30, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treat...

GlobeNewsWire - 10 months ago

BOSTON, March 18, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treat...

Market Watch - 1 year ago

Shares of Rhythm Pharmaceuticals Inc. RYTM, -2.64% were down 3% in trading on Tuesday, the day after the company announced that president and CEO Keith Gottesdiener plans to step down.

GlobeNewsWire - 1 year ago

Keith Gottesdiener, M.D. to Step Down as Chief Executive Officer Following NDA Submission for Setmelanotide in POMC and LEPR Deficiency Obesities Expected in the First Quarter of 2020

GlobeNewsWire - 1 year ago

-- Topline data expected in the fourth quarter of 2020 or early in the first quarter of 2021 -- -- Supplemental cohort continues enrollment to meet patient demand --

Zacks Investment Research - 1 year ago

Rhythm Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

GlobeNewsWire - 1 year ago

BOSTON, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the tre...

GlobeNewsWire - 1 year ago

BOSTON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the tre...

GlobeNewsWire - 1 year ago

BOSTON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the tre...

Seeking Alpha - 1 year ago

Liver Therapy Forum weekly digest provides an overview of what's happening in therapeutics for obesity in 2019. The focus this week is Rhythm Pharmaceuticals.

GlobeNewsWire - 1 year ago

-- Four new MC4R pathway obesity indications added to Phase 2 Basket Study and enrolling patients -- -- Genetic sequencing of 13,567 individuals with severe obesity yields 11.7 percent (1,5...

GlobeNewsWire - 1 year ago

-- Plan to expand ongoing Phase 2 Basket Study with four additional rare indications -- -- Sequenced nearly 14,000 people with early-onset, severe obesity; Yield suggests potential significant...

GlobeNewsWire - 1 year ago

BOSTON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare...

About RYTM

Rhythm Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2... [Read more...]

Industry
Biotechnology
IPO Date
Oct 5, 2017
CEO
Keith Gottesdiener
Employees
70
Stock Exchange
NASDAQ
Ticker Symbol
RYTM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for RYTM stock is "Buy." The 12-month stock price forecast is 35.75, which is an increase of 5.18% from the latest price.

Price Target
$35.75
(5.18% upside)
Analyst Consensus: Buy